ArticleAmerican journal of translational research2021
Efficacy of budesonide in the prevention and treatment of bronchopulmonary dysplasia in premature infants and its effect on pulmonary function.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.
- Efficacy of pharmacologic therapies for reducing bronchopulmonary dysplasia and mortality in preterm infants: a network meta-analysis.BMC pediatrics · 2026Pooled it
- Efficacy of pulmonary surfactant with budesonide in premature infants: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Efficacy and safety of intratracheal administration of budesonide combined with pulmonary surfactant in preventing bronchopulmonary dysplasia: a prospective randomized controlled trial.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Trial
- Bronchopulmonary Dysplasia and Innate Immunity: A Narrative Review of the Roles of IL-1β and IL-8 (CXCL8).Children (Basel, Switzerland) · 2026Review
- GSDMD deficiency ameliorates hyperoxia-induced BPD and ROP in neonatal mice.Scientific reports · 2023Article
- Comparison of clinical outcomes following delivery of budesonide by both vibrating mesh nebulizer and jet nebulizer in premature infants with bronchopulmonary dysplasia.Frontiers in pediatrics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was designed to explore the efficacy of budesonide (BUD) in preventing and treating bronchopulmonary dysplasia (BPD) in premature infants and its effect on pulmonary function.
methodsA total of 94 premature infants with BPD who were born in our hospital were selected as the research subjects and divided into the control group (47 cases) for routine treatment and the research group (47 cases) for BUD therapy on the basis of routine treatment according to the random number table method. The incidence of BPD and the time of oxygen inhalation, ventilator ventilation, extubation and hospitalization were recorded in the two groups. In addition, arterial blood gas indexes (arterial oxygen saturation (SaO
resultsAfter treatment, SaO
conclusionBUD is effective in the prevention and treatment of BPD in premature infants, which can effectively reduce the incidence of BPD and other complications, improve blood gas indexes, reduce inflammatory reactions and promotes good pulmonary function in children.
Indexed as
Identifiers
34150079PMC8205685W3176770554What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.